Back to Search
JOHN NEMUNAITIS, MD
MD
Medical Oncology Physician
NPI: 1164464269Individual
Specialties, Licenses & Credentials
Medical Oncology PhysicianPrimary
Internal Medicine — Medical Oncology
Code: 207RX0202X
J3859(TX)35.132707(OH)
Research & Publications (20)
Granulocyte-macrophage colony-stimulating factor gene-modified autologous tumor vaccines in non-small-cell lung cancer.
PMID 14970281·J Natl Cancer Inst·2004
3-trial
Phase I trial of topotecan in combination with gemcitabine in refractory solid tumor patients.
PMID 15493356·Cancer Invest·2004
3-trial
Enhanced oncolytic potency of replicative adenovirus expressing p53.
PMID 12654282·Drug Resist Updat·2003
7-preclinical
Pilot trial of intravenous infusion of a replication-selective adenovirus (ONYX-015) in combination with chemotherapy or IL-2 treatment in refractory cancer patients.
PMID 12719704·Cancer Gene Ther·2003
3-trial
Pilot trial of genetically modified, attenuated Salmonella expressing the E. coli cytosine deaminase gene in refractory cancer patients.
PMID 14502226·Cancer Gene Ther·2003
3-trial
Selective replicating viral vectors : potential for use in cancer gene therapy.
PMID 12899642·BioDrugs·2003
6-review
GVAX (GMCSF gene modified tumor vaccine) in advanced stage non small cell lung cancer.
PMID 12932654·J Control Release·2003
6-review
Head and neck cancer: gene therapy approaches. Part 1: adenoviral vectors.
PMID 11849117·Expert Opin Biol Ther·2002
6-review
Head and neck cancer: gene therapy approaches. Part II: genes delivered.
PMID 11890870·Expert Opin Biol Ther·2002
6-review
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 1325 CONFERENCE DR
TOLEDO, OH 43614 - Phone
- (419) 383-6644
Quick Facts
- NPI
- 1164464269
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Not confirmed
- Specialties
- 2
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile